Published Research & Clinical Data

Key finding
EC50 values of 85.7-192.4 µg/mL measured in vitro against SARS-CoV-2. Observed dual mechanism: interaction with viral replication and entry pathways. Non-cytotoxic to healthy cells.

Key finding
Clinical data documenting the extract's antiviral properties observed across multiple viral infection models.

Key finding
Confirmed broad-spectrum antimicrobial activity via membrane disruption — effective against both bacterial and fungal pathogens.

Key finding
Significant pain reduction and increased range of motion when Camelyn was combined with ultrasound-assisted delivery.

Key finding
Demonstrated immunomodulatory support in oncology patients, establishing foundation for 155-patient longitudinal review.

Key finding
Confirmed anti-tumor activity through immune system activation rather than direct cytotoxic action on cancer cells.

Key finding
First evidence of immunomodulatory mechanism — tumor growth regression via NK cell activation in animal models.

Key finding
Showed reduced tumor induction rates in treated groups compared to controls.

Key finding
Documented quality-of-life improvements and immune parameter normalization in advanced cancer patients.

Key finding
Demonstrated tumor growth inhibition and enhanced immune response markers in treated subjects.

Key finding
Tumor cells showed altered proliferation rates while healthy cells remained unaffected — early evidence of selective action.

Key finding
Reversed T-cell depression and stimulated interferon production in both patient groups — evidence of broad immunomodulatory action.

Key finding
One of the earliest systematic studies establishing anti-tumor activity of Georgian honey extract. Foundation for all subsequent research.

Key finding
Demonstrated immune parameter improvement in leukemia patients through combined therapy approach.

Key finding
Significant increase in phagocyte activity observed — the body's frontline immune cells became measurably more active.

Key finding
Longitudinal review of 155 patients documented immune parameter changes (IL-2, IFN-γ, TNF-α activation) and quality-of-life observations across multiple clinical settings.